Literature DB >> 392661

Bismuth toxicity in man II. Review of bismuth blood and urine levels in patients after administration of therapeutic bismuth formulations in relation to the problem of bismuth toxicity in man.

W J Serfontein, R Mekel.   

Abstract

A survey of the leterature on bismuth toxicity in man in relation to blood level data, has revealed the necessity of distinguishing between lipid soluble and water soluble organic complexes of bismuth on the one hand and the simple inorganic salts of bismuth on the other hand. A characteristic feature of the former, illustrated by the water soluble bismuth complex triglycollamate, is the high bismuth levels (due to absorption of the complex as such) and the nephrotoxic properties of the compound in man. Bismuth absorption after administration of the simple inorganic salts of bismuth is postulated to occur in the form of ionic bismuth as such, low bismuth levels being characteristic features of such compounds. Bismuth blood and urine levels obtained from patients after administration of a new anti-ulcer drug (Bicitropeptide) in a well controlled clinical trial are discussed and suggest that that this bismuth containing drug behaves pharmacologically in a manner similar to the inorganic bismuth salts in man, low bismuth blood levels and the absence of toxic side effects being conspicuous features of the drug. Based on these considerations, it is proposed that the pharmacologically active bismuth compounds be divided into four different groups depending on structure, stability and solubility. The question as to what constitutes a "toxic bismuth blood level" can only be discussed in relation to the new proposed sub-division of bismuth compounds and is only meaningful if the term is defined to relate only to ionic bismuth (presumably bound to a large extent to blood proteins). Based on information gleaned from the literature and blood level values reported in the clinical trial referred to, it is suggested that bismuth blood level values below 50 micrograms/ml are highly unlikely to be associated with meaningful toxicity in man. Finally, attention is drawn to the reversibility of bismuth toxicity in man as reported by many authors irrespective of the type of bismuth compound concerned.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 392661

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  12 in total

1.  In vitro cytotoxicity of surface modified bismuth nanoparticles.

Authors:  Yang Luo; Chaoming Wang; Yong Qiao; Mainul Hossain; Liyuan Ma; Ming Su
Journal:  J Mater Sci Mater Med       Date:  2012-07-17       Impact factor: 3.896

2.  Antacids for duodenal ulcer.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-09

3.  Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.

Authors:  Estelle Guiard; Bénédicte Lelievre; Magali Rouyer; Frank Zerbib; Bertrand Diquet; Francis Mégraud; François Tison; Emmanuelle Bignon; Régis Lassalle; Cécile Droz-Perroteau; Nicholas Moore; Patrick Blin
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

Review 4.  Renal effects of peptic ulcer therapy.

Authors:  E Burgess; D Muruve
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

5.  Disposition of bismuth in the rat. II. Pharmacokinetics and biliary excretion.

Authors:  N Rao; S Feldman
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

Review 6.  Extradural application of bismuth iodoform paraffin paste causing relapsing bismuth encephalopathy: a case report with CT and MRI studies.

Authors:  R R Sharma; I P Cast; R M Redfern; C O'Brien
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

Review 7.  Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis.

Authors:  Alexander C Ford; Peter Malfertheiner; Monique Giguere; Jose Santana; Mostafizur Khan; Paul Moayyedi
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

Review 8.  Pharmacokinetics and toxicity of bismuth compounds.

Authors:  A Slikkerveer; F A de Wolff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct

9.  Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes.

Authors:  Sung Eun Kim; Moo In Park; Seun Ja Park; Won Moon; Jae Hyun Kim; Kyoungwon Jung; Hae Koo Kim; Young Dal Lee
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

10.  Synthesis, X-ray Opacity, and Biological Compatibility of Ultra-High Payload Elemental Bismuth Nanoparticle X-ray Contrast Agents.

Authors:  Anna L Brown; Pratap C Naha; Victor Benavides-Montes; Harold I Litt; Andrea M Goforth; David P Cormode
Journal:  Chem Mater       Date:  2014-03-10       Impact factor: 9.811

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.